Page 3 - Aser Surgery News Today

Novo Nordisk’s strategy to grow beyond metabolic diseases includes expanding into adjacent areas such as cardiovascular disease. Acquiring Cardio Pharmaceuticals adds a novel RNA-based therapy that is a potential heart failure treatment.

Many women going through menopause suffer brain fog, but some may be worried about a more serious cognitive condition like dementia. Because of this, Midi Health and Neurotrack partnered to offer a cognitive assessment to patients.

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

The “holy grail” of ATMP-based treatments is to provide cures for some of the world’s most debilitating disease states, but for this to occur, a unified front is needed to democratize these therapies – collaboration from industry, academia, supply chain and, indeed, clinicians and hospitals is paramount to ensuring safe manufacturing and transit.

A new report from the Peterson Health Technology Institute analyzed eight digital diabetes management tools. It found that the tools don't provide meaningful clinical benefits and increase healthcare spending.

Lack of automation is the top challenge facing commercialization teams, according to a survey of executives at U.S.-based pharma companies. The survey was conducted in late 2023 and results were reported this month.

Join MedCity News and nearly 300 healthcare investors, startups, and innovative-minded executives in Chicago at the Ritz Carlton on May 21-22. Space is limited. Secure your spot today to attend!

With its acquisition of TAO Connect, UpLift now serves over 170 enterprise customers in the U.S. and Canada. It covers four million people, including more than two million students at more than 120 higher education institutions.

Four modest system improvements in the U.S. are assisting with valuing and activating people’s families and support networks in health care today.

On Monday at HIMSS24, Innovaccer unveiled a preview of its new AI copilot for providers, which is slated to go on the market by the end of 2024. The solution is a portable tablet device designed to provide clinicians with point-of-care support — it flags care and coding gaps, assists with clinical documentation and advises clinicians on possible diagnosis pathways.